As RESI returns to Boston, so does one of the event's most popular panels. The Big Pharma Panel features five high-level external innovation executives from top tier pharma companies, who will discuss their key motivators and strategies in depth. What indication areas are the most sought after? What can be expected in the due diligence process? How does an early stage entrepreneur interface with business development executives from pharmaceutical companies? LSN's Big Pharma RESI Panelists will shed light on these questions and more.
Moderated by Steve Yoder, Global Head, Specialty Pharmaceuticals Search and Evaluation, Bristol Myers Squibb this panel will feature:
Hear from big pharma executives as they explain how they engage with early stage startups, and how they like to be contacted. The speakers will help the audience understand their timeline for contact, and give advice on how to create a dialogue that leads to a relationship and an eventual alliance. If you need to understand the time frame and limitations of how big pharma corporate works, this expert session is crucial for you to attend...
- Michael Draper, Senior Director External Science & Partnering - East Coast, Sanofi
- Tomas Landh, Vice President, Senior Principal Scientist Innovation Sourcing, Novo Nordisk
- Kuldeep Neote, Senior Director, New Ventures/Scout, Johnson & Johnson Innovation
- Kiran Reddy, Senior Director, Corporate Strategy, Biogen